<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03883542</url>
  </required_header>
  <id_info>
    <org_study_id>sBOT</org_study_id>
    <nct_id>NCT03883542</nct_id>
  </id_info>
  <brief_title>Sub-type Specific Genomic Mutations in sBOTs</brief_title>
  <official_title>Sub-type Specific Genomic Mutations in Serous Borderline Ovarian Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to identify different origin in carcinogenesis between serous
      borderline ovarian tumors presenting a. without implants, b. with non-invasive implants, c.
      with invasive implants and d. with micropapillary pattern.

      The presence of specific mutations could suggest for a more aggressive primary treatment if a
      higher risk of recurrence can be expected.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction Borderline Ovarian Tumors (BOTs) behave indolently in the vast majority of cases
      and the prognosis is usually favorable. There is more evidence that two subtypes of BOTs
      represent a higher risk of recurrence or even progression to an invasive ovarian cancer. In
      case of a presentation with a micro-papillary grow pattern or when invasive implants are
      diagnosed the prognosis tend to be less favorable.

      Genome sequencing in ovarian cancer helped to differentiate two different pathways in the
      carcinogenesis.

      Low grade serous carcinomas evolving from adenofibromas or borderline tumors over
      non-invasive micropapillary serous borderline tumors to invasive micropapillary serous
      carcinoma, show frequent mutations in the Kirsten Rat Sarcoma gene (KRAS), B-Raf Kinase
      gene(BRAF), Erb-B2 Receptor Tyrosine Kinase 2 gene (ERBB2), Phosphatase and Tensin homolog
      gene (PTEN), Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene
      (PIK3CA) and Catenin Beta 1 gene (CTNNB1). This pathway is called Type I and is characterized
      by a slow step-wise process. These low-grade invasive tumors are indolent and are known with
      a better outcome than high-grade invasive tumors.

      In contrast the Type II pathway development of invasive tumors is rapid and vast majority of
      tumors show a Tumor Protein p53 (TP53) mutation and loss of Breast Cancer type 1
      susceptibility protein (BRCA1).

      The aim of this study is to identify different origin in carcinogenesis between serous
      borderline ovarian tumors presenting a. without implants, b. with non-invasive implants, c.
      with invasive implants and d. with micropapillary pattern.

      The presence of specific mutations could suggest for a more aggressive primary treatment if a
      higher risk of recurrence can be expected.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>genetic mutations</measure>
    <time_frame>2020</time_frame>
    <description>amount and type of genetic mutations in different subgroups will be analyzed and compared between the different subgroups. Are the mutations suggestive for a type I or type II pathway differentiation?</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ovarian Neoplasm Epithelial</condition>
  <arm_group>
    <arm_group_label>serous BOT</arm_group_label>
    <description>simple serous BOT ovarian tissue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>serous BOT with non-invasive implants</arm_group_label>
    <description>BOT ovarian tissue presenting with non-invasive implants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sBOT with micropapillary grow pattern</arm_group_label>
    <description>BOT ovarian tissue presenting with micropapillary grow pattern</description>
  </arm_group>
  <arm_group>
    <arm_group_label>serous BOT with invasive implants</arm_group_label>
    <description>sBOT ovarian tissue presenting with invasive implants at the time of diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>genomic mutations study</intervention_name>
    <description>Sequencing of the DNA samples extracted from the subgroups
serous BOT tissue,
serous BOT tissue with non-invasive implants and
serous BOT tissue with micropapillary grow pattern will undergo a panel testing for Type 1 genes (small panel 15-40 mutations) AND p53 AND BRCA testing
Sequencing of the DNA samples extracted from the serous BOT tissue with invasive implants will undergo a more comprehensive examination (large panel +- 1000 genes checked)</description>
    <arm_group_label>sBOT with micropapillary grow pattern</arm_group_label>
    <arm_group_label>serous BOT</arm_group_label>
    <arm_group_label>serous BOT with invasive implants</arm_group_label>
    <arm_group_label>serous BOT with non-invasive implants</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Macrodissection of borderline ovarian tumor tissue. DNA extraction from paraffin embedded
      material for genetic analysis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with proven serous bordeline ovarian tumors.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Paraffin embedded material from the original borderline ovarian tumor must be present
             and of good quality for DNA extraction.

          -  Original slides are available for central pathological review.

        Exclusion Criteria:

          -  Presence of invasive ovarian carcinoma.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Morice P, Uzan C, Fauvet R, Gouy S, Duvillard P, Darai E. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol. 2012 Mar;13(3):e103-15. doi: 10.1016/S1470-2045(11)70288-1. Review.</citation>
    <PMID>22381933</PMID>
  </reference>
  <reference>
    <citation>Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009 Sep;16(5):267-82. doi: 10.1097/PAP.0b013e3181b4fffa. Review.</citation>
    <PMID>19700937</PMID>
  </reference>
  <reference>
    <citation>Despierre E, Lambrechts D, Neven P, Amant F, Lambrechts S, Vergote I. The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol Oncol. 2010 May;117(2):358-65. doi: 10.1016/j.ygyno.2010.02.012. Epub 2010 Mar 7. Review.</citation>
    <PMID>20207398</PMID>
  </reference>
  <reference>
    <citation>Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010 Mar;34(3):433-43. doi: 10.1097/PAS.0b013e3181cf3d79.</citation>
    <PMID>20154587</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Stefan Cosyns</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>low malignant potential</keyword>
  <keyword>serous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

